Regulation Implementing EO on Insulin and Epinephrine Delayed

HRSA published a notice in the Federal Register officially delaying the effective date for new regulation implementing President Trump’s Executive Order (EO) on FQHC 340B prices for insulin and EpiPens. The effective date has been delayed by 60 days-–the maximum time allowed under the White House order–until March 22. Per the notice, this delay will “give Department officials the opportunity for further review and consideration of new regulations.” There have been some media coverage and social media posts mischaracterizing the regulation as well as the impact of its delay. For talking points if your health center is contacted or if you want to respond to misrepresentations, contact Eric Kiehl, PACHC Director of Policy & Partnership.